Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05063136 | Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer | recruiting | Phase 3 | 1,979 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06533384 | PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC | recruiting | Phase 3 | 310 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06669013 | Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas(FollowTheDIN) | recruiting | Phase 3 | 40 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT06288373 | Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC | recruiting | Phase 2 / Phase 3 | 440 | Tongji HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT04516681 | Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer | recruiting | Phase 3 | 400 | Fudan UniversityOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT05744219 | Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial(IRIS) | recruiting | Phase 3 | 338 | Jon UnossonOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT04921527 | Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer(CHIPRO) | recruiting | Phase 3 | 454 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Oct 18, 2024 | clinicaltrials |
| NCT04547166 | A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) | recruiting | Phase 2 / Phase 3 | 568 | Shanghai Henlius BiotechINDUSTRY | 2 | Oct 17, 2024 | clinicaltrials |
| NCT06275958 | DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer(DOSAGE) | recruiting | Phase 3 | 587 | Leiden University Medical CenterOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06498479 | ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer | recruiting | Phase 3 | 460 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05487391 | A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection. | recruiting | Phase 3 | 632 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06634966 | Segmentectomy for Solid-dominant Lung Cancer | recruiting | Phase 3 | 277 | Fudan UniversityOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05495152 | Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 219 | Henan Cancer HospitalOTHER_GOV | 1 | Oct 2, 2024 | clinicaltrials |
| NCT04638790 | First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)(HL-Russia-1) | recruiting | Phase 3 | 300 | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of RussiaOTHER | 2 | Sep 27, 2024 | clinicaltrials |
| NCT06607796 | Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy | recruiting | Phase 3 | 180 | Zhou ChengzhiOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06609551 | ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study(ZJCH-CRCC-1) | recruiting | Phase 3 | 312 | Zhejiang Cancer HospitalOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT06607419 | Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia(BBClean) | recruiting | Phase 2 / Phase 3 | 90 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06608381 | Comparison Partial Versus Total Omentectomy in Minimal Invasive Distal Gastrectomy for cT3/4a Gastric Cancer (KLASS-10) | recruiting | Phase 3 | 440 | Gangnam Severance HospitalOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT04547907 | A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer | recruiting | Phase 3 | 688 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 20, 2024 | clinicaltrials |
| NCT04332822 | A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma(POLAR BEAR) | recruiting | Phase 3 | 300 | Nordic Lymphoma GroupNETWORK | 7 | Sep 19, 2024 | clinicaltrials |
| NCT05168839 | Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage(FLUOCOL-1) | recruiting | Phase 3 | 1,010 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05512403 | Evaluation of Diagnostic Performances of 18F-FDOPA PET KInetics(KING) | recruiting | Phase 3 | 88 | Central Hospital, Nancy, FranceOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05613023 | A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT(PACE-NODES) | recruiting | Phase 3 | 1,128 | Institute of Cancer Research, United KingdomOTHER | 3 | Sep 19, 2024 | clinicaltrials |
| NCT06022861 | A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 510 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06248996 | a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients(ARTSCAN VI) | recruiting | Phase 3 | 308 | Lund University HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06559696 | Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy | recruiting | Phase 3 | 722 | Fujian Medical University Union HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06592326 | 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer | recruiting | Phase 3 | 460 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06585007 | Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer(MEDCARE) | recruiting | Phase 3 | 246 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT06523673 | Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer(OPPRESS) | recruiting | Phase 3 | 104 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT06041477 | Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC(HAIC) | recruiting | Phase 3 | 540 | Sun Yat-sen UniversityOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06185556 | COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases(COLDFIRE-III) | recruiting | Phase 2 / Phase 3 | 78 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT02131753 | Therapy Optimisation for the Treatment of Hairy Cell Leukemia | recruiting | Phase 2 / Phase 3 | 210 | University of GiessenOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06566755 | Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer | recruiting | Phase 3 | 30 | Caigang LiuOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06563869 | Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06187441 | FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)(HOVON174MM) | recruiting | Phase 3 | 599 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT05654454 | A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer | recruiting | Phase 3 | 620 | Mabscale, LLCINDUSTRY | 1 | Aug 16, 2024 | clinicaltrials |
| NCT06079346 | A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer(STOP-PC) | recruiting | Phase 2 / Phase 3 | 455 | Oncotelic Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06394492 | SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer | recruiting | Phase 3 | 440 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05939687 | Prophylactic Mesh Placement During Stoma Closure After Low Anterior Resection(ProMeLAR) | recruiting | Phase 3 | 142 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06522555 | The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma | recruiting | Phase 3 | 100 | Ruijin HospitalOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT05055908 | Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors(BECOME) | recruiting | Phase 3 | 12,000 | Hunan Province Tumor HospitalOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT05764044 | Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer(AddChemo) | recruiting | Phase 3 | 365 | Hospital do CoracaoOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06509724 | Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy(POHIM-P3) | recruiting | Phase 3 | 248 | Samsung Medical CenterOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06520176 | Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients | recruiting | Phase 3 | 99 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Jul 25, 2024 | clinicaltrials |
| NCT06521255 | Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 3 | 244 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 25, 2024 | clinicaltrials |
| NCT06138028 | Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer | recruiting | Phase 2 / Phase 3 | 90 | Qingdao Central HospitalOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06516133 | Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma(OART) | recruiting | Phase 3 | 494 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06509126 | Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer(IMPROVE-2) | recruiting | Phase 3 | 500 | National Cancer Institute, NaplesOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT06086457 | PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer | recruiting | Phase 3 | 436 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06383780 | Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. | recruiting | Phase 3 | 90 | XIANG YANQUNOTHER | 1 | Jul 16, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 4, 2024source: clinicaltrials